Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15 2019 - 5:30PM
Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced that the Company approved
the grant of an equity award to a new employee with a grant date
of November 11, 2019 as an equity inducement award
outside of the Company's 2017 Stock Incentive Plan and material to
the employee’s acceptance of employment with the Company. The
equity award was approved on September 20, 2019, in accordance
with Nasdaq Listing Rule 5635(c)(4).
The employee received an option to purchase 80,224 shares of
Apellis common stock. The option has an exercise price
of $29.03 per share, which is equal to the closing price
of Apellis common stock on November 11, 2019, the grant date
of the option. One-fourth of the shares underlying the employee
option will vest on the one year anniversary of the employee’s date
of employment and thereafter 1/48th of the shares underlying the
employee option will vest monthly, such that the shares underlying
the option granted to the employee will be fully vested on the
fourth anniversary of the employee’s date of hire, subject to the
employee’s continued employment with Apellis on such vesting
dates.
About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds for the treatment of a broad range of
life-threatening or debilitating autoimmune diseases based upon
complement immunotherapy through the inhibition of the complement
system at the level of C3. Apellis is the first company to advance
chronic therapy with a C3 inhibitor into clinical trials. For
additional information about Apellis and APL-2, please
visit http://www.apellis.com.
Apellis Forward-Looking Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to the implications of
preliminary clinical data. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
whether preliminary or interim results from a clinical trial will
be predictive of the final results of the trial; whether results
obtained in preclinical studies and clinical trials such as the
results reported in this release will be indicative of results that
will be generated in future clinical trials; whether APL-2 will
successfully advance through the clinical trial process on a timely
basis, or at all; whether the results of such clinical trials will
warrant regulatory submissions and whether APL-2 will receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies for
GA, PNH, C3G or any other indication; whether, if Apellis’ products
receive approval, they will be successfully distributed and
marketed; and other factors discussed in the “Risk Factors” section
of Apellis’ Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission on November
5, 2019 and the risks described in other filings that Apellis may
make with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact:Tracy
Vineistracy.vineis@apellis.com617.420.4839
Investor Contact: Sam Martin / Maghan
MeyersArgot Partners sam@argotpartners.com /
maghan@argotpartners.com212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Sep 2023 to Sep 2024